secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2026-08-11T20:07:48+00:00
Accession:  0001390478-26-000013
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Q2 2026 net loss $9.6M; GPS Phase 3 nears 80th-event final analysis
--------------------------------------------------------------------------

- Q2 2026 net loss $9.6M ($0.05/sh) vs $6.6M ($0.07/sh) in Q2 2025; H1 loss $18.0M.
- R&D expense $6.3M in Q2 2026 (vs $3.9M) on BLA prep for GPS; G&A $4.4M (vs $3.0M).
- Cash and equivalents $138.3M as of June 30, 2026.
- Phase 3 REGAL (GPS) in AML will conduct final analysis after pre-specified 80th event; timing unannounced.
- 28 patients enrolled in Phase 2 SLS009 frontline AML; topline data expected Q4 2026; preclinical PDAC data upcoming.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/0001390478-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001390478-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer